Paracetamol use prior to and in early pregnancy: Prevalence and patterns among women with and without chronic medical diseases
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Paracetamol use prior to and in early pregnancy : Prevalence and patterns among women with and without chronic medical diseases. / Taagaard, Mille; Rode, Line; de Wolff, Mie Gaarskjær; Damm, Peter; Hagen, Casper P.; Fisher, Margit Bistrup; Hegaard, Hanne Kristine; Rom, Ane Lilleøre.
In: British Journal of Clinical Pharmacology, Vol. 89, No. 8, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Paracetamol use prior to and in early pregnancy
T2 - Prevalence and patterns among women with and without chronic medical diseases
AU - Taagaard, Mille
AU - Rode, Line
AU - de Wolff, Mie Gaarskjær
AU - Damm, Peter
AU - Hagen, Casper P.
AU - Fisher, Margit Bistrup
AU - Hegaard, Hanne Kristine
AU - Rom, Ane Lilleøre
N1 - Publisher Copyright: © 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
PY - 2023
Y1 - 2023
N2 - Aims: Paracetamol is commonly consumed by pregnant women, even though recent data have questioned its safety. Having chronic medical diseases (CMDs) may influence the prevalence of use during pregnancy. We aimed to assess the prevalence and patterns of use 3 months prior to pregnancy and in the first trimester among women with and without CMDs and the potential influence of CMDs on frequent use in the first trimester. Methods: We used patient-reported data from the Copenhagen Pregnancy Cohort from 1 October 2013 to 23 May 2019 with information on CMDs and paracetamol use. Prevalence and patterns of use were assessed descriptively and by multivariable logistic regression models. Results: We included 24 019 pregnancies. Use of paracetamol prior to and in early pregnancy was significantly higher among women with CMDs compared to women without (40.7% vs. 35.8% and 9.1% vs. 5.1%, respectively). Women with CMDs were 2.7 times more likely to have a frequent intake compared to women without [aOR 2.69 (95% CI 2.05–3.32)]. Migraine, rheumatoid arthritis and mental disease were associated with a higher use of paracetamol [aOR 4.39 (3.20–6.02), aOR 4.32 (2.41–7.72) and aOR 2.74 (1.67–4.49), respectively]. Conclusions: Women with CMDs had a higher paracetamol use before and during pregnancy than women without CMDs. Women with migraine, rheumatoid arthritis and mental disease showed the highest risk of frequent use. This study highlights the importance of discussing pain relief in pregnancy and evaluating the influence of maternal CMDs when assessing adverse effects of paracetamol use during pregnancy.
AB - Aims: Paracetamol is commonly consumed by pregnant women, even though recent data have questioned its safety. Having chronic medical diseases (CMDs) may influence the prevalence of use during pregnancy. We aimed to assess the prevalence and patterns of use 3 months prior to pregnancy and in the first trimester among women with and without CMDs and the potential influence of CMDs on frequent use in the first trimester. Methods: We used patient-reported data from the Copenhagen Pregnancy Cohort from 1 October 2013 to 23 May 2019 with information on CMDs and paracetamol use. Prevalence and patterns of use were assessed descriptively and by multivariable logistic regression models. Results: We included 24 019 pregnancies. Use of paracetamol prior to and in early pregnancy was significantly higher among women with CMDs compared to women without (40.7% vs. 35.8% and 9.1% vs. 5.1%, respectively). Women with CMDs were 2.7 times more likely to have a frequent intake compared to women without [aOR 2.69 (95% CI 2.05–3.32)]. Migraine, rheumatoid arthritis and mental disease were associated with a higher use of paracetamol [aOR 4.39 (3.20–6.02), aOR 4.32 (2.41–7.72) and aOR 2.74 (1.67–4.49), respectively]. Conclusions: Women with CMDs had a higher paracetamol use before and during pregnancy than women without CMDs. Women with migraine, rheumatoid arthritis and mental disease showed the highest risk of frequent use. This study highlights the importance of discussing pain relief in pregnancy and evaluating the influence of maternal CMDs when assessing adverse effects of paracetamol use during pregnancy.
KW - acetaminophen
KW - chronic medical disease
KW - paracetamol
KW - pregnancy
U2 - 10.1111/bcp.15732
DO - 10.1111/bcp.15732
M3 - Journal article
C2 - 37016498
AN - SCOPUS:85153371063
VL - 89
JO - British Journal of Clinical Pharmacology, Supplement
JF - British Journal of Clinical Pharmacology, Supplement
SN - 0264-3774
IS - 8
ER -
ID: 359853435